Navigation Links
ASP Announces Availability of EVOTECH(TM) Endoscope Cleaner and Reprocessor - First Commercially Available System to Eliminate Manual Cleaning of Endoscopes
Date:12/16/2008

ins that offer cleaning and reprocessing in 33 minutes or less.
  • Convenient hands-free operation.
  • Audible alarm can be turned on to alert of cycle completion.
  • The EVOTECH(TM) System is indicated for use with high-level disinfectant CIDEX(R) OPA Concentrate Solution and an enzymatic detergent (CIDEZYME(R) GI) to achieve cleaning and high-level disinfection of heat sensitive (>60 degrees Celsius) semi-critical endoscopes. Manual cleaning of medical devices (endoscopes) is not required prior to placement in the EVOTECH(TM) System when selecting those cycles that contain a wash stage. Manual cleaning of medical devices (endoscopes) is required when selecting the Disinfect only or Disinfect/Alcohol Flush Cycle.

    For more information about the EVOTECH(TM) System, please visit www.evotechecr.com or call 1-888-783-7723.

    About ASP

    Advanced Sterilization Products (ASP), division of Ethicon, Inc., a Johnson & Johnson company, has a long track record of designing and delivering innovative infection prevention solutions that dramatically raise the level of health and safety for those who matter most. Our pioneering technology, global distribution, and established leadership position enable us to simplify the process of buying and operating infection prevention products and services every day, for thousands of medical facilities around the world. This in turn enables our customers to focus on what they do best - preventing infection and saving lives.

    www.evotechecr.com


    '/>"/>
    SOURCE Advanced Sterilization Products
    Copyright©2008 PR Newswire.
    All rights reserved

    Page: 1 2

    Related biology technology :

    1. Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
    2. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
    3. Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
    4. Bioamber announces worlds first bio-based succinic acid plant: helping to reduce dependence on fossil fuels
    5. OmegaGenesis Announces Angiogenesis Application Collaboration
    6. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
    7. Banyan Biomarkers Announces Issuance of U.S. Patent for Biomarkers for Traumatic Injury
    8. Osteotech Announces Stock Repurchase Program
    9. Martek Announces Fourth Quarter and FY 2008 Financial Results
    10. Helix BioPharma Announces Q1 2009 Financial Results
    11. Neogen Announces New Share Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6
    Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2From fruit fly wings to heart failure -- why Not(ch)? 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2Sunrise Reports Financial Results for Second Quarter 2009 53821 1Sunrise Reports Financial Results for Second Quarter 2009 53821 2Sunrise Reports Financial Results for Second Quarter 2009 53821 3Sunrise Reports Financial Results for Second Quarter 2009 53821 4Sunrise Reports Financial Results for Second Quarter 2009 53821 5Sunrise Reports Financial Results for Second Quarter 2009 53821 6Sunrise Reports Financial Results for Second Quarter 2009 53821 7Sunrise Reports Financial Results for Second Quarter 2009 53821 8Sunrise Reports Financial Results for Second Quarter 2009 53821 9Sunrise Reports Financial Results for Second Quarter 2009 53821 10Sunrise Reports Financial Results for Second Quarter 2009 53821 11Sunrise Reports Financial Results for Second Quarter 2009 53821 12Sunrise Reports Financial Results for Second Quarter 2009 53821 13Sunrise Reports Financial Results for Second Quarter 2009 53821 14Sunrise Reports Financial Results for Second Quarter 2009 53821 15Sunrise Reports Financial Results for Second Quarter 2009 53821 16Sunrise Reports Financial Results for Second Quarter 2009 53821 17Sunrise Reports Financial Results for Second Quarter 2009 53821 18Sunrise Reports Financial Results for Second Quarter 2009 53821 19Sunrise Reports Financial Results for Second Quarter 2009 53821 20Micromet Inc Reports Second Quarter 2009 Financial Results 53819 1Micromet Inc Reports Second Quarter 2009 Financial Results 53819 2Micromet Inc Reports Second Quarter 2009 Financial Results 53819 3Micromet Inc Reports Second Quarter 2009 Financial Results 53819 4Micromet Inc Reports Second Quarter 2009 Financial Results 53819 5Micromet Inc Reports Second Quarter 2009 Financial Results 53819 6Micromet Inc Reports Second Quarter 2009 Financial Results 53819 7Micromet Inc Reports Second Quarter 2009 Financial Results 53819 8Micromet Inc Reports Second Quarter 2009 Financial Results 53819 9Micromet Inc Reports Second Quarter 2009 Financial Results 53819 10Micromet Inc Reports Second Quarter 2009 Financial Results 53819 11Ben Shappley Joins Amedicas Leadership Team 53817 1Ben Shappley Joins Amedicas Leadership Team 53817 2